$87.05 general Payment -- AbbVie Inc to Dr. Christine Edwards

AbbVie Inc. makes $87.05 payment to Gastroenterologist Christine Edwards for services rendered.

This page provides a detailed analysis of a $87.05 general payment from AbbVie Inc to Dr. Christine Edwards. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$87.05
Payment Typegeneral
Payment NatureCompensation for services other than consulting
Pharmaceutical CompanyAbbVie Inc
PhysicianDr. Christine Edwards
NPI Number1578057490
Physician SpecialtyGastroenterology
LocationSan Francisco, CA
Date of Payment2024-10-06
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

AbbVie Inc made a $87.05 general payment to Christine Edwards, a Gastroenterology specialist in San Francisco, CA. The payment of $87.05 from AbbVie Inc. to Dr. Christine Edwards is for services other than consulting. This payment falls under the 'general' payment type, indicating a broad category of compensation. The payment was made on October 6, 2024, to a Gastroenterologist in San Francisco, CA.

Patient Guidance: What This Payment Means for You

This payment represents compensation for services provided by your doctor to a pharmaceutical company and is not a direct payment to you. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for services other than consulting are common in the pharmaceutical industry, but the specific nature and amount can vary widely by specialty and service.

Regulatory Context: Sunshine Act Requirements

This transaction is reported under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of payments made by drug and device manufacturers to physicians and teaching hospitals.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

What was this $87.05 payment for?

This was a general payment of $87.05 from AbbVie Inc to Christine Edwards, categorized as "Compensation for services other than consulting". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Christine Edwards accept pharmaceutical money?

Yes, Christine Edwards received this $87.05 payment from AbbVie Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Christine Edwards's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this general payment?

A general payment of $87.05 should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Gastroenterology?

To compare this payment against Gastroenterology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Gastroenterology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Christine Edwards's relationship with AbbVie Inc?

The payment amount is relatively small, suggesting a specific service or minor compensation. This $87.05 general payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Gastroenterology?

The payment is categorized as 'general', lacking specific details on the nature of services.

What should patients do after learning about this payment?

This payment represents compensation for services provided by your doctor to a pharmaceutical company and is not a direct payment to you.

What else should I know about this general payment?

The date of payment is recent, falling within the 2024 reporting period.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.